We bring on UniQure CEO Matt Kapusta to discuss the company's announcement this week that its one-time treatment for Huntington’s disease significantly slowed down the neurological condition in a key study.
We also chat about the Trump's administration initiatives on autism. Officials this week warned pregnant women not to take Tylenol, saying that it may c ... Show More
Sep 18
370: Pharma sours on the U.K., plus biotech M&A's quiet roll
STAT's European correspondent Andrew Joseph calls in from the U.K. to the podcast to dissect why companies like Merck and GSK are putting their money elsewhere. We also discuss the Advisory Committee on Immunization Practices, or ACIP, meeting and biotech M&A, including Roche's $ ... Show More
37m 21s
Feb 2025
Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original purpose - from treatin ... Show More
55m 40s
Jun 2020
Market Surge, Treatment Hopes, Retail Sales, Royalty Pharma CEO, SoftBank’s T-Mobile Stake
David Faber and Jim Cramer discuss the massive surge for stocks. Multiple reports emerging saying dexamethasone, a widely available drug, can help critically ill coronavirus patients. The treatment reportedly reduced Covid-19 deaths in hospitalized patients by up to one third. An ... Show More
45m 4s
Aug 2024
Market Rally Aims for “Cloud Nine,” Bronfman's Paramount Bid, Eli Lilly CEO on Weight-Loss Drug 8/20/24
Carl Quintanilla and Jim Cramer led off the show by delving into the broadening market rally, as the S&P 500 and Nasdaq aim for a ninth consecutive day of gains. David Faber called into the show with reporting on Edgar Bronfman's bid to acquire Paramount Global. Eli Lilly CEO Dav ... Show More
44m 46s
Jul 30
ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some i ... Show More
14m 39s
Nov 2024
Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges
What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s largest ... Show More
53m 58s
Jan 2025
AI, vaccine distrust, and the future of healthcare: Novartis CEO
Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline i ... Show More
25m 45s
Aug 10
Deep Dive: Novo Nordisk & Eli Lilly Stumble Into Next Phase of Ozempic Era
Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show More
11m 3s
May 2024
Tom Mueller, "How to Make a Killing: Blood, Death and Dollars in American Medicine" (Norton, 2023)
Dialysis is a medical miracle, a treatment that allows people with kidney failure to live when otherwise they would die. It also provides a captive customer for the dialysis industry, which values the steady revenues that come from critically required long-term care that is guara ... Show More
1h 9m